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There is ample evidence that patients with mel-
anoma can develop immune responses directed 
against antigens expressed by their own tumor 
(Boon et al., 2006). Among these antigens, 
cancer-germline antigens (CGAs) are expressed 
by tumors of many different histological types, 
including melanoma, but not by normal tis-
sues, except testis. Because germ cells in testis 
do not express HLA molecules on their surface 
(Haas et al., 1988), CGAs represent strictly 
tumor-specific T cell targets (Boon et al., 
2006). Among CGAs, NY-ESO-1 has been 
shown to stimulate spontaneous cellular and 
humoral responses that are detectable only in 
patients with advanced NY-ESO-1–expressing 
cancer (Stockert et al., 1998; Jäger et al., 2000; 
Mandic et al., 2005; Fourcade et al., 2008). 
Understanding the failure of spontaneous NY-
ESO-1–specific T cell responses to promote 
regression of NY-ESO-1+ tumors is therefore 
critical for the design of novel therapeutic inter-
ventions aimed at overcoming tumor-induced 
immune escape.
We have previously shown that the large 
majority of spontaneous NY-ESO-1–specific 
CD8+ T cells up-regulates programmed death 1 
(PD-1) expression (Fourcade et al., 2009), which 
appears to be associated with T cell exhaustion/
dysfunction in chronic viral infections in animals 
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The paradoxical coexistence of spontaneous tumor antigen–specific immune responses with 
progressive disease in cancer patients furthers the need to dissect the molecular pathways 
involved in tumor-induced T cell dysfunction. In patients with advanced melanoma, we 
have previously shown that the cancer-germline antigen NY-ESO-1 stimulates spontaneous 
NY-ESO-1–specific CD8+ T cells that up-regulate PD-1 expression. We also observed that 
PD-1 regulates NY-ESO-1–specific CD8+ T cell expansion upon chronic antigen stimulation. 
In the present study, we show that a fraction of PD-1+ NY-ESO-1–specific CD8+ T cells in 
patients with advanced melanoma up-regulates Tim-3 expression and that Tim-3+PD-1+ 
NY-ESO-1–specific CD8+ T cells are more dysfunctional than Tim-3PD-1+ and Tim-3PD-1 
NY-ESO-1–specific CD8+ T cells, producing less IFN-, TNF, and IL-2. Tim-3–Tim-3L block-
ade enhanced cytokine production by NY-ESO-1–specific CD8+ T cells upon short ex vivo 
stimulation with cognate peptide, thus enhancing their functional capacity. In addition, 
Tim-3–Tim-3L blockade enhanced cytokine production and proliferation of NY-ESO-1–
specific CD8+ T cells upon prolonged antigen stimulation and acted in synergy with PD-1–
PD-L1 blockade. Collectively, our findings support the use of Tim-3–Tim-3L blockade 
together with PD-1–PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction 
in patients with advanced melanoma.
© 2010 Fourcade et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS
Tim-3 expression is up-regulated on NY-ESO-1– 
specific CD8+ T cells
Using HLA-A2 (A2) tetramers, we assessed Tim-3 expres-
sion by flow cytometry on the surface of spontaneous ex vivo 
detectable NY-ESO-1–specific CD8+ T cells and CMV-, 
EBV-, and influenza (Flu)-specific CD8+ T cells isolated 
from PBMCs of nine HLA-A*0201+ (HLA-A2+) stage 
IV melanoma patients and nine HLA-A2+ healthy donors. 
In melanoma patients, frequencies of Tim-3+ cells among 
NY-ESO-1–specific CD8+ T cells (mean 28.8% ± SD 20.7%) 
were significantly higher than those of CMV-specific CD8+ 
T cells (8.8 ± 4.9%; P = 0.0156) and EBV-specific CD8+  
T cells (11.6 ± 13.8%; P = 0.0313; Fig. 1, A and B). The mean 
percentage of Tim-3 expression on NY-ESO-1–specific CD8+  
T cells was similar to the one observed on Flu-specific 
CD8+ T cells, although Tim-3 expression on Flu-specific 
CD8+ T cells was more homogenous among patients than on 
NY-ESO-1–specific CD8+ T cells (29.8 ± 10.8%; P = 0.1563). 
The percentages of Tim-3+ NY-ESO-1–specific CD8+  
T cells in melanoma patients were consistently higher than 
those of Tim-3+ effector (CD45RA+CCR7) and effector 
memory (CD45RO+CCR7) CD8+ T cells (4.6% ± 1.6% 
and 3.3% ± 3.2%, respectively; P = 0.0156). Similar observa-
tions were made when analyzing Tim-3 expression as mean 
fluorescence intensity (MFI), with the exception that Tim-3 
MFI was higher on total effector than on total effector mem-
ory CD8+ T cells (77.7 ± 29.5 versus 38 ± 23.7, respectively; 
P = 0.0422; Fig. 1 B, right).
In healthy donors, frequencies of Tim-3+ cells were also 
significantly higher among Flu-specific CD8+ T cells (24.8 ± 
15%) than among CMV- and EBV-specific CD8+ T cells (6.8 ± 
3.2% and 3.1 ± 3.3%, respectively; P = 0.0223; Fig. 1 C). As 
expected, no spontaneous NY-ESO-1–specific CD8+ T cells 
were detectable in PBMCs from healthy donors. The mean 
percentage of Tim-3+ cells and the mean Tim-3 MFI were 
significantly higher for total effector (CD45RA+CCR7) 
than for total effector memory (CD45RO+CCR7) CD8+ 
T cells (9.8 ± 5.9% versus 3.1 ± 2.1% and 81.3 ± 24.9 versus 
35.6 ± 13.4, respectively; P = 0.0089 and P = 0.0039).
We have assessed Tim-3 expression on different subsets 
of mononuclear cells, including CD4+ T cells, CD8+ T cells, 
NK cells (CD56+), B cells (CD19+), monocytes (CD14+), 
and myeloid DCs (mDCs; CD11c+) isolated from PBMCs of 
six melanoma patients and six healthy donors. We found that 
Tim-3 expression is up-regulated on the surface of NK cells, 
monocytes, and mDCs in melanoma patients and healthy do-
nors. However, within these cell subsets, no significant differ-
ence was observed for Tim-3 expression between melanoma 
patients and healthy donors (Fig. S1).
As the majority of spontaneous NY-ESO-1–specific 
CD8+ T cells in melanoma patients up-regulates PD-1 ex-
pression (Fourcade et al., 2009), we next determined whether 
Tim-3 and PD-1 are expressed on identical or distinct T cell 
subsets. Using HLA-A2 tetramers, NY-ESO-1–, CMV-, 
EBV-, and Flu-specific CD8+ T cells present in PBMCs of 
and humans (Barber et al., 2006; Day et al., 2006; Petrovas et al., 
2006; Trautmann et al., 2006). We observed that PD-1 up- 
regulation on spontaneous NY-ESO-1–specific CD8+ T cells 
occurs along with T cell activation and is not directly associated 
with an inability to produce cytokines ex vivo upon stimula-
tion with cognate antigen. Blockade of the PD-1–programmed 
death ligand 1 (PD-L1) pathway in combination with pro-
longed antigen stimulation with PD-L1+ APCs or melanoma 
cells augmented the frequencies of cytokine-producing, prolif-
erating, and total NY-ESO-1–specific CD8+ T cells. Our 
findings are in line with previous studies of PD-1 expression 
by HIV- and SIV-specific CD8+ T cells, demonstrating that 
PD-1 is a regulator of antigen-specific CD8+ T cell expansion 
in the context of chronic antigen exposure, although it does 
not exhibit a major impact upon their functionality on a cell-
per-cell basis (Petrovas et al., 2006, 2007). To further determine 
whether other molecular pathways are involved in tumor 
antigen–specific T cell dysfunction, we studied T cell immuno-
globulin and mucin-domain–containing molecule 3 (Tim-3) 
expression on spontaneous NY-ESO-1–specific CD8+ T cells 
from patients with advanced melanoma and investigated 
whether Tim-3 up-regulation defines a subgroup of dysfunc-
tional tumor antigen–specific CD8+ T cells. Tim-3 is a trans-
membrane protein constitutively expressed on Th1/Tc1 cells 
in mice and humans (Monney et al., 2002). Several lines of 
evidence support the role of Tim-3 as an inhibitory molecule 
that down-regulates effector Th1/Tc1 cell responses. In mice, 
blocking the Tim-3–Tim-3L pathway resulted in hyperprolif-
eration of Th1-type cells and abrogated the induction of 
peripheral and transplantation tolerance (Sabatos et al., 2003; 
Sánchez-Fueyo et al., 2003). Tim-3 interacts with its ligand 
galectin-9 to induce cell death in Th1 cells (Zhu et al., 2005). 
In humans, Tim-3 expression is defective in CD4+ T cells 
producing high levels of IFN-, as well as those isolated from 
cerebrospinal fluid of patients with multiple sclerosis (Koguchi 
et al., 2006). Recently, Tim-3 up-regulation has been reported 
in HIV-specific and HCV-specific CD8+ T cells in patients 
with progressive HIV infection and chronic hepatitis C, respec-
tively (Jones et al., 2008; Golden-Mason et al., 2009). Tim-3+ 
HIV- and HCV-specific CD8+ T cells were distinct from the 
PD-1+ CD8+ T cells and exhibited T cell dysfunction. How-
ever, it is unknown whether tumor antigen–specific CD8+  
T cells in patients with advanced cancers express Tim-3.
In this study, we show that a fraction of PD-1+ NY-ESO-1– 
specific CD8+ T cells, which represents the large majority of 
circulating NY-ESO-1–specific CD8+ T cells in patients with 
advanced melanoma, up-regulates Tim-3 expression. Tim-3+ 
PD-1+ NY-ESO-1–specific CD8+ T cells are highly dysfunc-
tional compared with Tim-3PD-1+ and Tim-3PD-1 
NY-ESO-1–specific CD8+ T cells. Tim-3–Tim-3L pathway 
blockade alone or in combination with PD-1–PD-L1 pathway 
blockade enhanced NY-ESO-1–specific CD8+ T cell numbers 
and functions. Collectively, our findings support the use of 
Tim-3–Tim-3L blockade in association with PD-1–PD-L1 
blockade to reverse tumor-induced T cell exhaustion/ 
dysfunction in patients with advanced melanoma.
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Figure 1. Tim-3 is up-regulated and coexpressed with PD-1 on NY-ESO-1–specific CD8+ T cells. (A) Representative dot plots from melanoma 
patients (MP) showing ex vivo Tim-3 expression on A2/NY-ESO-1 157–165, A2/EBV BMLF-1 280–288, A2/CMV 495–503, and A2/Flu-M 58–66 tet+ CD8+  
T cells. As shown for one melanoma patient (MP1), CD8+ T cells stained with A2/HIVpol 476–484 tetramers or PE-labeled IgG control Ab were used to 
establish the threshold for identifying tet+ cells and Tim-3+ cells, respectively. (B and C) Pooled data showing the percentage (%) and MFI of Tim-3 expres-
sion on NY-ESO-1–, CMV-, EBV-, and Flu-specific CD8+ T cells, as well as total effector (CD45RA+ CCR7) and effector/memory (CD45RO+ CCR7) CD8+  
T cells from nine melanoma patients (B) and nine healthy donors (C). (D) Dot plots from one representative melanoma patient showing ex vivo Tim-3 and  
PD-1 expression on A2/NY-ESO-1 157–165, A2/EBV BMLF-1 280–288, A2/CMV 495–503 and A2/Flu-M 58–66 tet+ CD8+ T cells. As control, A2/NY-ESO-1 
157–165 tet+ CD8+ T cells stained with PE-labeled and FITC-labeled IgG control antibodies are shown. (E) Pooled data showing the distribution of NY-ESO-1–, 
CMV-, EBV-, and Flu-specific CD8+ T cells, as well as total tet CD8+ T cells according to Tim-3 and PD-1 expression. Horizontal bars depict the mean  
percentage or MFI of Tim-3 and/or PD-1 expression on tet+ CD8+ T cells. The p- values were calculated using the Wilcoxon signed rank test. Data shown  
are representative of at least three independent experiments.
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fractions of NY-ESO-1–specific CD8+ T cells were assessed 
after gating on NY-ESO-1–specific CD8+ T cells, including 
A2/NY-ESO-1 157–165 tetramer+ (tet+) and cytokine- 
producing CD8+ T cells (Fig. 2 A, left). Cytokine production 
was restricted to NY-ESO-1–specific CD8+ T cells, as no 
cytokine was produced by A2/NY-ESO-1 157–165 tet+ CD8+ 
T cells after incubation with HIV peptide. As shown for one 
melanoma patient in Fig. 2 A (right) and for seven melanoma 
patients in Fig. 2 B (left), Tim-3+ NY-ESO-1–specific CD8+ 
T cells produced significantly less IFN- (P = 0.0156), TNF 
(P = 0.0156), and IL-2 (P = 0.0313) than Tim-3 NY-ESO-
1–specific CD8+ T cells. In six out of seven melanoma pa-
tients tested, we also investigated the capacity of Tim-3+ and 
Tim-3 Flu-specific CD8+ T cells to produce cytokines 
ex vivo upon short stimulation with cognate peptide–pulsed 
APCs. Tim-3+ Flu-specific CD8+ T cells produced signifi-
cantly less IL-2 and TNF than Tim-3 Flu-specific CD8+  
T cells (P = 0.0313). However, the difference in the percent-
ages of TNF-producing cells between Tim-3+ and Tim-3 
subsets was much lower for the Flu-specific CD8+ T cells 
(mean 73 ± 11.6% versus 89.9 ± 6.5%, respectively) than for 
the NY-ESO-1–specific CD8+ T cells (mean 9.8 ± 12.8% 
versus 38 ± 24.3%; Fig. 2 B, right). In addition, we measured 
no difference in IFN- production between Tim-3+ and 
Tim-3 Flu-specific CD8+ T cells (P = 0.0625). To better 
understand the major differences in cytokine production be-
tween Tim-3+ and Tim-3 NY-ESO-1– and Flu-specific 
CD8+ T cells, we next investigated whether Tim-3+ NY-
ESO-1–specific CD8+ T cells, which also coexpress PD-1 in 
their large majority (mean 86.1% of total Tim-3+ NY-ESO-
1–specific CD8+ T cells) represent a more dysfunctional pop-
ulation than Tim-3+ Flu-specific CD8+ T cells, which 
coexpress PD-1 only in their minority (mean 19.5% of total 
Tim-3+ Flu-specific CD8+ T cells). To this end, we costained 
NY-ESO-1–specific CD8+ T cells from patients for Tim-3 
and PD-1 and analyzed cytokine production after 6hr- 
stimulation with cognate peptide. As shown for one melanoma 
patient in Fig. 2C and for seven melanoma patients in Fig. 2 D, 
Tim-3+PD-1+ NY-ESO-1–specific CD8+ T cells produced 
significantly less IFN- (P = 0.0156), TNF (P = 0.0156), and 
IL-2 (P = 0.0313) than Tim-3PD-1 cells. We did not 
observe significant differences in cytokine production be-
tween Tim-3PD-1+ and Tim-3PD-1 NY-ESO-1–specific 
CD8+ T cells, confirming our previous findings that PD-1 
up-regulation is not directly associated with an inability to pro-
duce cytokines upon ex vivo stimulation (Fourcade et al., 2009). 
Strikingly, in one melanoma patient with very high levels of 
spontaneous NY-ESO-1–specific CD8+ T cells (Fig. 2 C), 
we observed that Tim-3+PD-1 NY-ESO-1–specific CD8+ 
T cells produced less IFN- and TNF than Tim-3PD-1 
NY-ESO-1–specific CD8+ T cells (67 versus 81% and 49 
versus 77%, respectively), suggesting that Tim-3 expression 
alone defines a population of dysfunctional T cells, as previ-
ously reported for HIV-specific CD8+ T cells (Jones et al., 
2008). Furthermore, we observed in the same patient that 
Tim-3+PD-1+ NY-ESO-1–specific CD8+ T cells produced 
nine melanoma patients were costained ex vivo for Tim-3 and 
PD-1 and analyzed by flow cytometry. We observed that 
Tim-3 expression on NY-ESO-1–specific CD8+ T cells (mean 
of Tim-3+ NY-ESO-1–specific CD8+ T cells: 28.8 ± 20.7% 
of total NY-ESO-1–specific CD8+ T cells; Fig.1 B) was asso-
ciated with PD-1 expression, as the mean percentage of 
Tim-3+PD-1+ cells among total NY-ESO-1–specific CD8+ 
T cells was significantly higher than the mean percentage of 
Tim-3+PD-1 NY-ESO-1–specific CD8+ T cells (24.8 ± 
18.7% versus 4 ± 3.9%, respectively; P = 0.0039; Fig. 1, 
D and E). Among total NY-ESO-1–specific CD8+ T cells, 
Tim-3 NY-ESO-1–specific CD8+ T cells (mean 71.2 ± 
20.7% of total NY-ESO-1–specific CD8+ T cells; Fig. 1 B) 
were predominantly PD-1+ (mean 54.2 ± 20.1%) and Tim-
3PD-1 represented a smaller subset (mean 17 ± 8%; Fig. 1, 
D and E). In sharp contrast with our findings of Tim-3 and 
PD-1 expression on NY-ESO-1–specific CD8+ T cells, 
CMV-, EBV-, and Flu-specific CD8+ T cells in the same 
melanoma patients were in their large majority Tim-3PD-1 
(means 75.7 ± 8.5%, 65.4 ± 10.2%, and 52.2 ± 12.6% of total 
virus-specific CD8+ T cells, respectively) and displayed very 
low frequencies of Tim-3+PD-1+ cells (means 2.1 ± 1.2%, 
2.9 ± 1.4%, and 6.1 ± 4.1% of total virus-specific CD8+  
T cells, respectively). In addition, and in contrast to NY-ESO-
1–specific CD8+ T cells, Tim-3 and PD-1 were mainly ex-
pressed by distinct populations among CMV-, EBV-, and 
Flu-specific CD8+ T cells (Fig. 1, D and E). Strikingly, 
although the levels of Tim-3 expression on Flu-specific CD8+  
T cells were similar to those of NY-ESO-1–specific CD8+  
T cells (mean of Tim-3+ Flu-specific CD8+ T cells, 29.8 ± 
10.8% of total Flu-specific CD8+ T cells; Fig. 1 B), Tim-3+ 
Flu-specific CD8+ T cells were predominantly PD-1 (mean 
24.3 ± 15%) and PD-1+ cells represented a much smaller 
fraction (mean 5.5 ± 3.1%; Fig. 1 E). Among total CD8+  
T cells, frequencies of Tim-3+ PD-1+ CD8+ T cells were lower 
than those of Tim-3PD-1, Tim-3PD-1+ and Tim-3+PD-
1CD8+ T cells in melanoma patients and healthy donors. 
Notably, Tim-3+PD-1+ NY-ESO-1–specific CD8+ T cells 
represented up to 33% of total Tim-3+PD-1+ CD8+ T cells 
in melanoma patients (unpublished data).
Collectively, our results demonstrate that Tim-3 expres-
sion is up-regulated on tumor-induced NY-ESO-1–specific 
CD8+ T cells and on Flu-specific CD8+ T cells in advanced-
stage melanoma patients with a heterogeneous expression 
observed on NY-ESO-1–specific CD8+ T cells. In addition, 
the vast majority of Tim-3+ NY-ESO-1–specific, but not 
Flu-, EBV-, and CMV-specific CD8+ T cells, up-regulates 
PD-1 expression.
Tim-3+PD-1+ NY-ESO-1–specific CD8+ T cells represent  
a dysfunctional T cell population
We next compared the ability of Tim-3+ and Tim-3 NY-
ESO-1–specific CD8+ T cells to produce cytokines ex vivo 
upon short stimulation (6 h) with cognate peptide–pulsed 
APCs (autologous CD3 cells). Percentages of IFN-–, 
TNF-, and IL-2–producing cells within Tim-3+ and Tim-3 
JEM VOL. 207, September 27, 2010 
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Figure 2. Co-expression of Tim-3 and PD-1 by NY-ESO-1–specific CD8+ T cells defines a population of dysfunctional T cells that  
up-regulate activation markers. (A and B) Representative dot plots from one melanoma patient (A) and summary data for melanoma patients (n = 7; B) 
showing the percentage of cytokine-producing A2/NY-ESO-1 157–165 tet+ and A2/Flu-M 58–66 tet+ CD8+ T cells among Tim-3+ and Tim-3 fractions  
after short ex vivo stimulation (6 h) with cognate peptide or irrelevant peptide (HIV peptide). (C and D) Dot plots from one patient (C) and summary  
data for all melanoma patients (n = 7; D) showing the percentages of cytokine-producing A2/NY-ESO-1 157–165 tet+ CD8+ T cells according to Tim-3  
and PD-1 expression. (E) Pooled data from melanoma patients (n = 7) showing expression of CD38, HLA-DR, CD57, CCR7, and CD45RA on A2/NY-ESO-1  
157–165 tet+ CD8+ T cells according to Tim-3 and PD-1 expression. The p-values were calculated using the Wilcoxon signed rank test. Data shown are  
representative of at least three independent experiments.
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Ex vivo blockade of the Tim-3–Tim-3L pathway enhances 
NY-ESO-1–specific CD8+ T cell cytokine production
We next tested whether Tim-3+PD-1+ NY-ESO-1–specific 
CD8+ T cell function augmented by blocking the interaction 
of Tim-3 with its ligands during a short ex vivo stimulation 
(6 h). Purified CD8+ T cells isolated from PBMCs of eight 
melanoma patients with spontaneous NY-ESO-1–specific 
CD8+ T cells were incubated with APCs (autologous CD3 
cells) pulsed with peptide NY-ESO-1 157–165 or peptide 
HIVpol 476–484 as control, in the presence of blocking 
mAbs against Tim-3 (clone 2E2) and/or anti–PD-L1 or IgG 
control antibodies. After stimulation with cognate peptide 
and anti–Tim-3 mAbs, we observed an increase in total NY-
ESO-1–specific CD8+ T cells that produced IFN- (P = 
0.0156) and TNF (P = 0.0469; Fig. 3, A and B). In contrast, 
no significant increase in IL-2–producing NY-ESO-1–specific 
CD8+ T cells was observed (P = 0.5469; unpublished data). 
PD-1–PD-L1 blockade in combination with Tim3–Tim-3L 
blockade did not further enhance the capacity of NY-ESO-1–
specific CD8+ T cells to produce IFN- (P = 0.0680), TNF 
(P = 0.8438), and IL-2 (P = 0.2188; unpublished data) as 
compared with incubation with anti–Tim-3 mAbs alone. 
In agreement with our previous findings, PD-1–PD-L1 
blockade alone did not increase cytokine production by NY-
ESO-1–specific CD8+ T cells upon short ex vivo stimulation 
with cognate peptide (Fourcade et al., 2009). We observed 
no cytokine production by NY-ESO-1 157–165–specific 
CD8+ T cells after short ex vivo stimulation (6 h) with an ir-
relevant peptide with or without Tim-3 and/or PD-1 block-
ade (Fig. S3 A). We also observed that Tim-3 pathway 
blockade did not significantly enhance cytokine production 
by CMV-specific CD8+ T cells, which express low levels of 
Tim-3 ex vivo (Fig. 3 C).
Tim-3–Tim-3L blockade alone or in combination  
with PD-1–PD-L1 blockade increases the frequency  
of cytokine-producing NY-ESO-1–specific CD8+ T cells 
upon prolonged antigen stimulation
We next assessed the impact of Tim-3 expression on cyto-
kine production by NY-ESO-1–specific CD8+ T cells after a 
multiday in vitro stimulation (IVS) with peptide-pulsed APCs. 
PBMCs from nine melanoma patients with spontaneous NY-
ESO-1–specific CD8+ T cell response were incubated for 6 d 
with NY-ESO-1 157–165 peptide in the presence of mAbs 
against Tim-3 and/or PD-L1 or IgG control antibodies. 
After 6 d, cells were shortly restimulated (6 h) with NY-
ESO-1 peptide or HIV peptide as control before evaluating 
cytokine production by A2/NY-ESO-1 157–165 tet+ CD8+ 
T cells. We observed a significant increase in the frequencies 
of NY-ESO-1–specific CD8+ T cells that produced IFN- 
and TNF (P = 0.0039 and P = 0.0091, respectively) after in-
cubation in the presence of cognate peptide and anti–Tim-3 
mAbs, as compared with cognate peptide and IgG control 
(Fig. 4, A and B), resulting in a 1.6- and 1.8-fold change in 
the frequencies of IFN-– and TNF-producing NY-ESO-1–
specific CD8+ T cells, respectively (Fig. 4 C). The frequency 
less IFN- and TNF than Tim-3+PD-1 NY-ESO-1–specific 
CD8+ T cells (53% versus 67% and 27% versus 49%, respec-
tively), suggesting that Tim-3+PD-1+ NY-ESO-1–specific 
CD8+ T cells represent a highly dysfunctional T cell popula-
tion. Notably, the low frequencies of Tim-3+PD-1 NY-
ESO-1–specific CD8+ T cells did not allow us to evaluate 
their function in six out of the seven melanoma patients tested. 
Collectively, our findings demonstrate that Tim-3+PD-1+ NY-
ESO-1–specific CD8+ T cells are highly dysfunctional in terms 
of cytokine production.
Tim-3+PD-1+ NY-ESO-1–specific CD8+ T cells exhibit high 
levels of T cell activation
We next assessed the differentiation/activation status of 
NY-ESO-1–specific CD8+ T cells according to the expression 
of Tim-3 and/or PD-1. We have compared the percentages 
of CD8+ T cells from PBMCs of seven stage IV melanoma 
patients that express the following markers ex vivo: CD38, 
HLA-DR, CD57, CCR7, CD45RA, CD27, and CD28 
among Tim-3PD-1, Tim-3PD-1+, and Tim-3+PD-1+ 
A2/NY-ESO-1 157–165 tet+ CD8+ T cells. The expression 
of the activation markers CD38, HLA-DR, and CD57 was 
higher on Tim-3PD-1+ than on Tim-3PD-1 NY-ESO-
1–specific CD8+ T cells (P = 0.0313, 0.0313, and 0.0223, respec-
tively; Fig. 2 E). CD38 and HLA-DR were further up-regulated 
on Tim-3+PD-1+ NY-ESO-1–specific CD8+ T cells than on 
Tim-3PD-1+ cells (P = 0.0156), whereas both populations 
expressed similar levels of CD57 (P = 0.4461; Fig. 2 E). The 
percentages of CCR7+ or CD45RA+ Tim-3+PD-1+ NY-
ESO-1–specific CD8+ T cells were similar to Tim-3PD-1+ 
NY-ESO-1–specific CD8+ T cells (P = 0.1058 and P = 0.4618, 
respectively), but lower than Tim-3PD-1 NY-ESO-1–specific 
CD8+ T cells (P = 0.0343 and P = 0.0156, respectively). 
In addition, the large majority (>80%) of Tim-3+PD-1+, 
Tim-3PD-1+, and Tim-3PD-1 NY-ESO-1–specific 
CD8+ T cells were CD27+ and CD28 (unpublished data).
In six melanoma patients, we assessed the expression of 
CD38, HLA-DR, CD57, CCR7, CD45RA, CD27, and 
CD28 on A2/Flu-M 58–66 tet+ CD8+ T cells, which do not 
coexpress Tim-3 and PD-1 in their large majority. We ob-
served that Flu-specific CD8+ T cells displayed a less acti-
vated phenotype than NY-ESO-1–specific CD8+ T cells, 
expressing lower levels of CD38, HLA-DR, and CD57. As 
compared with NY-ESO-1–specific CD8+ T cells, Flu- 
specific CD8+ T cells expressed higher levels of CD45RA, 
whereas no significant differences in terms of CCR7, CD27, 
and CD28 expression were observed. Therefore, Flu-specific 
CD8+ T cells include a higher proportion of effector cells 
(CCR7CD45RA+) than NY-ESO-1–specific CD8+ T cells 
that, by their large majority, are effector/memory CD8+  
T cells (CCR7CD45RA; Fig. S2).
Altogether, our findings show that Tim-3+PD-1+ NY-
ESO-1–specific CD8+ T cells represent a highly activated 
T cell subset that exhibit a maturation/differentiation status 
similar to that of Tim-3PD-1+ NY-ESO-1–specific CD8+ 
T cells.
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depicted), suggesting a synergistic effect of Tim-3–Tim-3L 
and PD-1–PD-L1 blockades on NY-ESO-1–specific CD8+ 
T cell expansion. This increase resulted in a 1.9-, 2.3-, and 
2.4-fold change in the frequencies of IFN--, TNF-, and 
IL-2–producing NY-ESO-1–specific CD8+ T cells, respec-
tively, when compared with IgG control antibody (Fig. 4 C). 
As control, PBMCs were incubated with an irrelevant peptide 
for 6 d in the presence of anti–Tim-3 or anti–PD-L1 mAbs. 
We did not observe a significant effect of Tim-3 or PD-1 
pathway blockade on the frequency of cytokine-producing 
NY-ESO-1–specific CD8+ T cells after restimulation with 
cognate peptide (Fig. S3 B). Notably, we observed that 
of IL-2–producing NY-ESO-1–specific CD8+ T cells increased 
in a majority of patients in the presence of cognate peptide 
and anti–Tim-3 mAbs alone, albeit the difference was not 
statistically significant when compared with IgG control (P = 
0.1829). We further observed a significant increase in the 
frequencies of not only IFN-– and TNF- but also IL-2–
producing NY-ESO-1–specific CD8+ T cells in the presence 
of both anti–Tim-3 and anti–PD-L1 mAbs when compared 
with IgG control antibodies (P = 0.0039), anti–Tim-3 mAbs 
alone (P = 0.0283, P = 0.0117, and P = 0.0418, respec-
tively), and anti–PD-L1 mAbs alone (P = 0.0177, P = 0.0091, 
and P = 0.0128, respectively; Fig. 4, A and B and not 
Figure 3. Ex vivo blockade of the Tim-3–Tim-3L pathway enhances cytokine production by NY-ESO-1–specific CD8+ T cells. (A and B) Repre-
sentative dot plots from one melanoma patient (A) and summary data for all melanoma patients (n = 8; B) showing the percentages of A2/NY-ESO-1 
157–165 tet+ CD8+ T cells that produce IFN- and TNF among total NY-ESO-1–specific CD8+ T cells after short ex vivo stimulation with cognate peptide 
in the presence of blocking anti–Tim-3 and/or anti–PD-L1 mAbs or an isotype control antibody (IgG). (C) Summary data for melanoma patients (n = 6) 
showing the percentages of A2/CMV 495–503 tet+ CD8+ T cells that produce IFN- and TNF among total CMV-specific CD8+ T cells after short ex vivo 
stimulation with cognate peptide in the presence of blocking anti–Tim-3 and/or anti–PD-L1 mAbs or an isotype control antibody (IgG). The p-values were 
calculated using the Wilcoxon signed rank test. Data shown are representative of two independent experiments performed in duplicate.
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Tim-3–Tim-3L blockade increased the percentages of NY-
ESO-1–specific CD8+ T cells that produced TNF and IL-2, 
but not IFN-, among total NY-ESO-1–specific CD8+ T cells 
compared with incubation with IgG control antibody (P = 
0.0090, P = 0.0128, and P = 0.1094, respectively; Fig. S4). 
This observation is in line with our data showing that Tim-3– 
Tim-3L blockade ex vivo enhances the functionality of NY-
ESO-1–specific CD8+ T cells. Although PD-1–PD-L1 
blockade alone did not significantly change the capacity of 
NY-ESO-1–specific CD8+ T cells to produce cytokines (i.e., 
no increase in the percentages of cytokine-producing cells 
among total NY-ESO-1–specific CD8+ T cells; Fig. S4), we 
observed that Tim-3–Tim-3L blockade in combination with 
PD-1–PD-L1 blockade augmented the percentages of NY-
ESO-1–specific CD8+ T cells that produced TNF and IL-2 
compared with incubation with IgG control antibody (P = 
0.0078 and P = 0.0039, respectively) or Tim-3–Tim-3L 
blockade alone (P = 0.0433 and P = 0.0117, respectively; 
Fig. S4). This increase resulted in a 1.3- and 2.2-fold change 
in the percentages of TNF- and IL-2–producing NY-ESO-1– 
specific CD8+ T cells among total NY-ESO-1–specific 
CD8+ T cells, respectively, when compared with IgG control 
antibody (Fig. S4), indicating a synergistic effect of Tim-3–
Tim-3L and PD-1–PD-L1 blockades. Notably, we observed 
a significant increase in the expression of PD-1 and Tim-3 by 
NY-ESO-1–specific CD8+ T cells after a 6-d IVS in the 
presence of cognate peptide and IgG control antibodies as 
compared with incubation with an irrelevant peptide (Fig. S5). 
These findings are in line with our previous observation of 
Tim-3 and PD-1 up-regulation by activated NY-ESO-1–
specific CD8+ T cells. Interestingly, Tim-3 or PD-1 block-
ade in the presence of cognate peptide induced a modest but 
significant increase in PD-1 and Tim-3 expression, respec-
tively, by NY-ESO-1–specific CD8+ T cells, but not by 
NY-ESO-1 tet CD8+ T cells, compared with incubation 
with cognate peptide and IgG control antibodies (Fig. S5). 
The up-regulation of Tim-3 and PD-1 expression by NY-
ESO-1–specific CD8+ T cells after PD-1 or Tim-3 blockade 
in the presence of cognate peptide is likely caused by higher 
levels of T cell activation and may possibly contribute to the 
synergistic effects of Tim-3 and PD-1 blockades.
Figure 4. Blockade of the Tim-3–Tim-3L pathway alone or in 
combination with PD-1–PD-L1 blockade with prolonged antigen 
stimulation increases the frequency of cytokine-producing  
NY-ESO-1–specific CD8+ T cells. (A and B) Representative flow cytom-
etry analysis from one melanoma patient showing percentages of IFN--, 
TNF-, and IL-2–producing A2/NY-ESO-1 157–165 tet+ CD8+ T cells among 
total CD8+ T cells (A) and pooled data from melanoma patients (n = 9) 
showing the variation in the frequencies of IFN-–, TNF-, and IL-2– 
producing NY-ESO-1 tet+ cells for 106 CD8+ T cells (B). PBMCs were incubated 
for 6 d with NY-ESO-1 157–165 peptide or with HIVpol 476–484 peptide 
and blocking anti–Tim-3 (aTim-3) and/or anti–PD-L1 (aPD-L1) mAbs or an 
isotype control antibody (IgG) before evaluating intracellular cytokine 
production of A2/NY-ESO-1 157–165 tet+ CD8+ T cells in response to 
cognate peptide. (C) Fold change of the frequency of IFN-–, TNF-, and 
IL-2–producing A2/NY-ESO-1 157–165 tet+ CD8+ T cells after 6-d IVS with 
cognate peptide and blocking anti–Tim-3 and/or anti–PD-L1 mAbs. The 
ratio of the frequency of cytokine-producing tet+ CD8+ T cells from mela-
noma patients (n = 9) in the presence of indicated antibody treatment  
and isotype control antibody is shown. The p-values were calculated  
using the Wilcoxon signed rank test. Data shown are representative of 
two independent experiments performed in duplicate.
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T cells evaluated in our study and HIV-specific CD8+  
T cells (Jones et al., 2008), spontaneous Tim-3+ NY-ESO-1– 
specific CD8+ T cells coexpress PD-1 in patients with ad-
vanced melanoma.
Tim-3–Tim-3L blockade alone or in combination  
with PD-1–PD-L1 blockade increases proliferation  
of NY-ESO-1–specific CD8+ T cells
Next, we evaluated whether Tim-3–Tim-3L blockade alone 
or in combination with PD-1–PD-L1 blockade increased 
proliferation of NY-ESO-1–specific CD8+ T cells in response 
to the cognate antigen in a multiday IVS. CFSE-labeled PBMCs 
from nine melanoma patients with spontaneous NY-ESO-1–
specific CD8+ T cell response were stimulated for 6 d with 
NY-ESO-1 157–165 peptide in the presence of mAbs against 
Tim-3 and/or PD-L1 or IgG control antibodies. As control, 
PBMCs were incubated for 6 d with HIVpol 476–484 pep-
tide. As shown in Fig. 5 A for two melanoma patients and 
in Fig. 5 (B and C) for nine patients, the addition of anti–
Tim-3 mAbs augmented the frequencies of CFSElo and total 
A2/NY-ESO-1 157–165 tet+ CD8+ T cells stimulated in the 
presence of cognate peptide as compared with peptide and 
IgG control antibody (P = 0.0117 and P = 0.0039, respec-
tively), resulting in a 1.9- and a 1.6-fold change in the fre-
quencies of CFSElo and total A2/NY-ESO-1 157–165 tet+ 
CD8+ T cells, respectively (Fig. 5, D and E). In line with 
previous findings (Fourcade et al., 2009), PD-1–PD-L1 
blockade in the presence of cognate peptide enhanced prolif-
erating and total NY-ESO-1–specific CD8+ T cells (P = 0.0117 
and P = 0.0039, respectively; Fig. 5 A and not depicted), re-
sulting in a 1.7- and a 1.5-fold change in the frequencies of 
CFSElo and total A2/NY-ESO-1 157–165 tet+ CD8+ T cells, 
respectively (Fig. 5, D and E). Importantly, blockade of both 
Tim-3–Tim-3L and PD-1–PD-L1 pathways further in-
creased the frequencies of CFSElo and total A2/NY-ESO-1 
157–165 tet+ CD8+ T cells as compared with stimulation 
with IgG control antibodies (P = 0.0078 and P = 0.0039, re-
spectively; Fig. 5, A–C), Tim-3 blockade alone (P = 0.0078 
and P = 0.0039, respectively), or PD-L1 blockade alone (P = 
0.0324 and P = 0.0078, respectively). This synergistic effect 
resulted in the highest increases in the frequencies of CFSElo 
and total A2/NY-ESO-1 157–165 tet+ CD8+ T cells (2.6- 
and 2.0-fold, respectively) as compared with stimulation with 
IgG control antibody (Fig. 5, D and E). No proliferation of 
NY-ESO-1 157–165-specific CD8+ T cells was observed 
after a 6-d IVS with an irrelevant peptide with or without 
Tim-3 and/or PD-1 blockade (Fig. S3 C).
DISCUSSION
In this study, we show that Tim-3+PD-1+ NY-ESO-1–specific 
CD8+ T cells represent a highly dysfunctional population of 
tumor-induced T cells in patients with advanced melanoma. 
We first observed that Tim-3 expression is up-regulated on 
tumor-induced NY-ESO-1–specific CD8+ T cells and on 
Flu-specific CD8+ T cells in advanced stage melanoma pa-
tients as compared with CMV-specific and EBV-specific ef-
fector and effector/memory CD8+ T cells. Strikingly, and in 
contrast not only to total EBV- and CMV-specific CD8+  
T cells but also to Flu-specific CD8+ T cells, the majority 
of Tim-3+ NY-ESO-1–specific CD8+ T cells up-regulates 
PD-1 expression. Therefore, unlike virus-specific CD8+  
Figure 5. Blockade of the Tim-3–Tim-3L pathway alone or in 
combination PD-1–PD-L1 blockade with prolonged antigen  
stimulation increases the frequency of proliferating and total  
NY-ESO-1–specific CD8+ T cells. Representative flow cytometry analysis 
from two melanoma patients showing percentages of CFSElo A2/NY-ESO-1 
157–165 tet+ CD8+ T cells among total CD8+ T cells (A) and pooled data 
from melanoma patients (n = 9) showing the variation in the numbers  
of CFSElo (B) and total (C) A2/NY-ESO-1 157–165 tet+ cells for 106 CD8+  
T cells. CFSE-labeled PBMCs were incubated for 6 d with NY-ESO-1 157–
165 peptide or HIVpol 476–484 peptide and blocking anti–Tim-3 (aTim-3), 
and/or anti–PD-L1 (aPD-L1) mAbs or an isotype control antibody (IgG).  
(D and E) Fold change of the frequencies of CFSElo (D) and total (E) A2/NY-
ESO-1 157–165 tet+ CD8+ T cells after 6-d IVS with cognate peptide and 
blocking anti–Tim-3 (aTim-3) and/or anti–PD-L1 (aPD-L1) mAbs (n = 9). 
The ratio of the percentages of CFSElo and total A2/NY-ESO-1 157–165 
tet+ CD8+ T cells in the presence of indicated antibody treatment and 
isotype control antibody is shown. The p-values were calculated using the 
Wilcoxon signed rank test. Data shown are representative of two inde-
pendent experiments performed in duplicate.
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but not blocking anti–PD-L1 mAbs, suggesting the critical 
role of the Tim-3–Tim3L pathway. Second, Tim-3 blockade 
in the presence of cognate peptide did not increase the 
frequency of cytokine-producing, CMV-specific CD8+  
T cells, which express low levels of Tim-3, suggesting that the 
blockade’s effect requires Tim-3 up-regulation by antigen-
specific T cells.
In addition, Tim-3 blockade in combination with pro-
longed antigen stimulation with cognate peptide increased 
the frequencies of cytokine-producing, proliferating, and 
total NY-ESO-1–specific CD8+ T cells, confirming the impact 
of the Tim-3–Tim-3L pathway on NY-ESO-1–specific T cell 
dysfunction. Strikingly, we also observed increased percentages 
of TNF- and IL-2–producing CD8+ T cells among total NY-
ESO-1–specific CD8+ T cells, supporting the role of Tim-3 
blockade in enhancing NY-ESO-1–specific CD8+ T cell 
functions on a cell-per-cell basis.
One novel finding is that Tim-3–Tim-3L blockade in 
combination with PD-1–PD-L1 blockade further increased 
the frequencies of not only IFN-– and TNF- but also IL-2–
producing NY-ESO-1–specific CD8+ T cells, as well as the 
frequencies of proliferating and total NY-ESO-1–specific 
CD8+ T cells, upon prolonged stimulation with cognate anti-
gen. It is likely that the enhanced capacity of NY-ESO-1–
specific CD8+ T cells to produce IL-2 after Tim-3–Tim-3L 
blockade alone and, to a larger extent, after both Tim-3–Tim-3L 
and PD-1–PD-L1 blockades contributed to the increased 
frequencies of proliferating NY-ESO-1–specific CD8+ T cells. 
Collectively, our data demonstrate a synergistic effect of 
Tim-3–Tim-3L and PD-1–PD-L1 blockades on NY-ESO-1–
specific CD8+ T cell functions.
In summary, our data demonstrate that Tim-3+PD-1+ 
NY-ESO-1–specific CD8+ T cells represent a highly dys-
functional population of tumor-induced T cells in patients 
with advanced melanoma. They show that Tim-3–Tim-3L 
blockade can partially restore NY-ESO-1–specific CD8+ T cell 
numbers and functions and acts in synergy with PD-1– 
PD-L1 blockade. Therefore, our data support the use of   Tim-3–
Tim-3L blockade in association with PD-1–PD-L1 blockade in 
immunotherapeutic interventions to reverse tumor-induced 
T cell exhaustion/dysfunction in patients with advanced mela-
noma. One caveat is the disruption of the Tim-3–Tim-3L path-
way appears to contribute to autoimmunity (Koguchi et al., 
2006). Therefore, it will be critical to carefully monitor the 
occurrence of serious autoimmune side effects in vivo.
MATERIALS AND METHODS
Study subjects. Blood samples were obtained under the University of Pitts-
burgh Cancer Institute Internal Revue Board–approved protocols 00–079 
and 05–140 from 19 HLA-A2+ patients with NY-ESO-1–expressing stage 
IV melanoma. NY-ESO-1 expression by patients’ tumors was assessed by 
RT-PCR and immunohistochemistry. All patients had serum NY-ESO-1–
specific antibodies detected by ELISA assays. Frequencies of NY-ESO-1–
specific CD8+ T cells were assessed ex vivo by flow cytometry using 
PE-labeled HLA-A2/NY-ESO-1 157–165 tetramers. Nine patients who 
exhibited spontaneous NY-ESO-1–specific CD8+ T cell responses were 
included in the study. The percentages of ex vivo detectable NY-ESO-1 
One critical finding is that Tim-3+PD1+ NY-ESO-1– 
specific CD8+ T cells are more dysfunctional than Tim3PD-1+ 
and Tim3PD-1 CD8+ T cells, as they produced signifi-
cantly less IFN-, TNF, and IL-2 ex vivo. We found no signifi-
cant difference in terms of cytokine production between 
Tim3PD-1 and Tim-3PD-1+ NY-ESO-1–specific CD8+ 
T cells, suggesting that PD-1 up-regulation alone without 
Tim-3 up-regulation is not directly associated with T cell 
dysfunction (i.e., cytokine secretion). This observation is in 
line with our previous demonstration that PD-1 acts as a reg-
ulator of NY-ESO-1–specific CD8+ T cell expansion upon 
chronic antigen exposure and has no major impact on their 
functionality on a cell-per-cell basis (Fourcade et al., 2009). 
In one melanoma patient with very high levels of spontane-
ous NY-ESO-1–specific CD8+ T cells, we found that Tim-
3+PD-1 NY-ESO-1–specific CD8+ T cells produced less 
cytokines than Tim-3PD-1 NY-ESO-1–specific CD8+  
T cells, suggesting that Tim-3 up-regulation alone by tumor 
antigen–specific CD8+ T cells defines a group of dysfunctional 
T cells independently of PD-1 up-regulation. Importantly, 
Tim-3+PD-1+ NY-ESO-1–specific CD8+ T cells produced 
significantly less cytokines than Tim-3+PD-1 NY-ESO-1–
specific CD8+ T cells, supporting Tim-3+PD-1+ CD8+ T cells, 
as a more dysfunctional population than Tim-3+PD-1 CD8+ 
T cells. The low frequencies of Tim-3+PD-1 NY-ESO-1–
specific CD8+ T cells did not allow us to extend this observa-
tion to the other melanoma patients included in our study. 
Interestingly, one study in mice with chronic persistent infec-
tions has shown that coexpression of multiple inhibitory re-
ceptors, including PD-1, LAG-3, 2B4, and CD160 by the 
same virus-specific CD8+ T cells was associated with lower 
T cell functions (Blackburn et al., 2009). Our findings further 
add to this observation and support that coexpression of 
Tim-3 and PD-1 is a marker of tumor-induced T cell dys-
function in patients with advanced melanoma.
We observed that blockade of the Tim-3–Tim-3L path-
way ex vivo increased the percentages of NY-ESO-1-specific 
CD8+ T cells that produced cytokines, supporting the role of 
the Tim-3 pathway in tumor antigen–specific T cell exhaus-
tion/dysfunction. These findings are in line with one study 
demonstrating the role of Tim-3 blockade in improving 
Tim-3+ HIV-specific CD8+ T cell functions (Jones et al., 2008). 
Although we could not measure the percentages of cytokine-
producing Tim-3+ NY-ESO-1–specific CD8+ T cells in wells 
containing the blocking anti–Tim-3 mAbs, it is tempting to 
speculate that the increased frequencies of cytokine-produc-
ing NY-ESO-1–specific CD8+ T cells occurred only within 
the Tim-3+ NY-ESO-1–specific CD8+ T cell compartment, 
which represents a fraction of total NY-ESO-1–specific CD8+ 
T cells (mean 28.8%) and includes a minority of cytokine-
producing cells (mean 8.7 and 4.6% of IFN-– and TNF-
producing Tim-3+ NY-ESO-1–specific CD8+ T cells among 
total NY-ESO-1–specific CD8+ T cells, respectively). Several 
lines of evidence support this assumption. First, the increase 
of cytokine-producing NY-ESO-1–specific CD8+ T cells was 
observed only in the presence of blocking anti–Tim-3 mAbs, 
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patients and six healthy donors. Fig. S2 depicts the activation and matura-
tional status of Flu-M 58–66–specific CD8+ T cells isolated from PBMCs of 
melanoma patients. Fig. S3 shows that Tim-3 and PD-1 pathway blockades 
in the absence of cognate peptide stimulation have no effect on NY-ESO-1–
specific CD8+ T cell cytokine production and proliferation. Fig. S4 demon-
strates that blockade of the Tim-3/Tim-3L pathway alone or in combination 
with PD-1/PD-L1 blockade with prolonged antigen stimulation enhances 
NY-ESO-1–specific CD8+ T cell functionality. Fig. S5 depicts the effect 
of Tim-3 and PD-1 pathway blockades on PD-1 and Tim-3 expression by 
NY-ESO-1–specific CD8+ T cells. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20100637/DC1.
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The minimum percentage of antigen-specific CD8+ T cells detected ex vivo 
in patients using these tetramers was 0.010% of total CD8+ T cells. Next, 
cells were stained with PD-1-FITC or IgG1-FITC (BD), Tim-3-PE (R&D 
Systems), or IgG2a-PE (BD)–, CD3-ECD–, and CD8-PE-Cy7 (Beckman 
Coulter)–conjugated antibodies. A violet amine–reactive dye (Invitrogen) 
was used to assess the viability of the cells. Alternatively, after tetramer label-
ing, cells were stained with the following conjugated antibodies and reagents: 
PD-1-FITC, CD8-ECD or CD8-PE-Cy7, HLA-DR-ECD, CD45RO-ECD 
(Beckman Coulter), CD38-PerCp-Cy5.5, CCR7-biotin (BD), CD28-
PerCp-Cy5.5, CD57-biotin (BD), CD45RA-PerCp-Cy5.5, CD27-Alexa750 
(eBioscience), and streptavidin-Alexa Fluor 750 (Invitrogen). 2.5 million events 
were collected during flow cytometric analysis on a FACSAria machine 
(BD) and analyzed using FlowJo software (Tree Star, Inc.).
Intracellular cytokine staining assay. For ex vivo cytokine production 
assays, 2 million purified CD8+ T cells were incubated for 6 h in 10% human 
serum DME Iscove medium with non-CD3 autologous cells pulsed with 
HLA-A2–restricted peptides NY-ESO-1 157–165, Flu-M 58–66, CMV 
495–503, or HIVpol 476–484 (10 µg/ml) in the presence of 10 µg/ml anti–
Tim-3 (clone 2E2) or anti–PD-L1 (16–5983; eBioscience) blocking mAbs 
or isotype control antibodies (BioLegend). For IVS assays, 5 million PBMCs 
were incubated for 6 d in culture medium containing 50 IU/ml rhIL-2 (Pepro-
Tech) with peptide NY-ESO-1 157–165 or peptide HIVpol 476–484 
(10 µg/ml) in the presence of 10 µg/ml anti–Tim-3 and/or anti–PD-L1 block-
ing mAbs or isotype control antibodies. On day 6, cells were restimulated for 6 h 
with peptide NY-ESO-1 157–165 or HIVpol 476–484 as control (10 µg/ml). 
After 1 h of incubation, Brefeldin A (Sigma-Aldrich) was added to the culture 
medium (10 µg/ml). Cells were then stained with APC-labeled HLA-A2/ 
NY-ESO-1 157–165, HLA-A2/Flu-M 58–66, or HLA-A2 CMV 495–503 tetra-
mers, PD-1-FITC, Tim-3-PE, CD8-Pacific Blue (Invitrogen), CD14-ECD, 
CD19-ECD, CD56-biotin, and streptavidin-ECD (Beckman Coulter) conju-
gated antibodies. Intracellular staining was performed with IFN--PE-Cy7, 
TNF-Alexa Fluor 700 (BD), and IL-2-PerCp-Cy5.5 (BioLegend) antibodies. 
2.5 million events were collected during flow cytometric analysis.
CFSE proliferation assay. 5 million CFSE-labeled PBMCs were incu-
bated for 6 d in culture medium containing 50 IU/ml rhIL-2 with peptide 
NY-ESO-1 157–165 or HIVpol 476–484 (10 µg/ml), in the presence of 
10 µg/ml anti–Tim-3 and/or anti–PD-L1 blocking mAbs or isotype control 
antibodies. On day 6, cells were stained with PE-labeled HLA-A2/NY-ESO-1 
157–165 tetramers, CD14-ECD, CD19-ECD, CD56-biotin, streptavidin-
ECD, CD8-PE-Cy7, and CD3-PE-Cy5.5 (Invitrogen) conjugated antibodies. 
2.5 million events were collected during flow cytometric analysis.
Statistics. Statistical hypotheses were tested with the Wilcoxon signed rank 
test (for paired results from the same patient) using SAS v. 9.1. Tests were 
two-sided, and P ≤ 0.05 was considered significant. Because rank tests are 
not sensitive to the actual values in a comparison, only to their ranks, differ-
ing sets of values can produce identical p-values.
Online supplemental material. Fig. S1 shows Tim-3 expression on dif-
ferent subsets of mononuclear cells isolated from PBMCs of six melanoma 
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